ARCHIVES

FDA Proposes To Drop Specific Requirements For Reprint Distribution On Off-Label Uses.

This article is from The Cancer Letter archive.

Vol. 34 No. 07 | February 22, 2008

Download PDF Visit The Full Archive

Related Articles

AVEO’s Tizozanib Fails in Colorectal Cancer

January 10, 2014

In Brief: AACR, ASCO to Sponsor Joint Symposium on Oncogenes; AACI Hosts Congressional Staff

February 15, 1985

ODAC Recommends FDA Approval For Grain Tumor Implant

June 21, 1996

How a two-faced media covered cancer: Promoting research—and cigarettes

April 29, 2022

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

December 16, 2011

DePinho’s Letter to CPRIT’s Gimson, And Gimson’s Response

June 1, 2012